Clinical Chemistry AACC Online Job Center
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 44: 1947-1950, 1998;
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow A correction has been published
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (7)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ocal, I. T.
Right arrow Articles by Green, T. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ocal, I. T.
Right arrow Articles by Green, T. R.
Related Collections
Right arrow Laboratory Management
Right arrow Evidence Based Laboratory Medicine and Test Utilization
Right arrow Drug Monitoring and Toxicology
(Clinical Chemistry. 1998;44:1947-1950.)
© 1998 American Association for Clinical Chemistry, Inc.

Drug Monitoring and Toxicology

Serum digoxin in the presence of Digibind: determination of digoxin by the Abbott AxSYM and Baxter Stratus II immunoassays by direct analysis without pretreatment of serum samples

Idris T. Ocal, and Terrence R. Greena

a Author for correspondence. Fax 503-494-8148; e-mail greent{at}ohsu.edu.

We have reevaluated the feasibility of using direct immunochemical methods to track free digoxin in patients receiving Digibind®. We report here that results obtained by the Stratus II and AxSYM immunoassays on patients receiving digoxin (without Digibind), digoxin-fortified serum samples supplemented with Digibind, and a digitoxic patient treated with Digibind, show no clinically significant biases. We conclude that useful free digoxin concentrations may be obtained for Digibind-treated patients using either the AxSYM or Stratus immunoassays without subjecting samples to ultrafiltration before analysis.




The following articles in journals at HighWire Press have cited this article:


Home page
 Clin. Chem.Home page
G. A. McMillin, W. E. Owen, T. L. Lambert, B. K. De, E. L. Frank, P. R. Bach, T. M. Annesley, and W. L. Roberts
Comparable Effects of DIGIBIND and DigiFab in Thirteen Digoxin Immunoassays
Clin. Chem., September 1, 2002; 48(9): 1580 - 1584.
[Full Text] [PDF]

Home page
 Clin. Chem.Home page
P. Rainey, I. T. Ocal, and T. R. Green
Digibind and Free Digoxin • The authors of the article cited above respond:
Clin. Chem., May 1, 1999; 45(5): 719 - 721.
[Full Text] [PDF]

Home page
 Clin. Chem.Home page
R. Valdes Jr. and S. A. Jortani
Monitoring of Unbound Digoxin in Patients Treated with Anti-Digoxin Antigen-binding Fragments: A Model for the Future?
Clin. Chem., September 1, 1998; 44(9): 1883 - 1885.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1998 by the American Association for Clinical Chemistry.